Airway Therapeutics was created in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center (CCHMC). Our goal is to bring innovation and expertise in protein therapeutics development for applications in the lung and pediatrics disciplines.
Each member of Airway’s management team brings more than 20 years of experience in academic and industrial research and development, drug development for rare diseases, along with experience in bringing development products to market.
Marc Salzberg, MDPresident & Chief Executive Officer
Jan holds a Ph.D. in Pharmaceutical Chemistry from UCSF and a postdoctoral fellowship in Clinical Pharmacology from Stanford University.
Jan S. Rosenbaum, PhDChief Scientific Officer
Andrew Levy, CPA, MBA, CBA Chief Financial Officer
Paul V. RemsenVice President Manufacturing
Anita FauchierVice President Regulatory Affairs and Quality
Jeffrey A. Whitsett, MD is Professor of Pediatrics, Chief of the Section of Neonatology, Perinatal and Pulmonary Biology, and Executive Director of the Perinatal Institute at Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine. Dr. Whitsett received his B.A. from Colgate University and his medical degree from Columbia University. He trained in Pediatrics at Mt. Sinai Hospital, New York City and in Neonatal-Perinatal Medicine at the Children’s Hospital Medical Center, University of Cincinnati College of Medicine. Following his fellowship he joined the faculty at the University of Cincinnati College of Medicine in 1977 and since has risen through the ranks to Professor. He is internationally known for his research in pulmonary medicine, as well as for his clinical expertise in neonatology. Dr. Whitsett has made a series of groundbreaking contributions in pulmonary medicine and biology in his studies of the surfactant proteins A, B, C and D, cloning their genes and clarifying their roles in lung development and function. Throughout his career, Dr. Whitsett has transitioned from molecular biology to animal models and then to the diagnosis and therapy of human disease. Importantly, he has played a critical role in making surfactant protein replacement routine in the treatment of immature lungs and respiratory distress syndrome in premature infants. Notably, his laboratory has contributed to the identification of a number of genes critical for lung formation and function and shown that mutations in genes regulating surfactant homeostasis are responsible for acute and chronic lung disease in infants and adults. Dr. Whitsett is the author of over 500 papers in both the basic science and clinical literature.
Dr. Whitsett is a member of the Institute of Medicine of the National Academy of Sciences and the recipient of various awards, including the Mead Johnson Award, a National Institutes of Health (NIH) Merit Award, the William Cooper Procter Award from Cincinnati Children’s, the Amberson Lecture Award of the American Thoracic Society, the prestigious Daniel Drake Medal for scientific contributions from the University of Cincinnati College of Medicine, the highly respected Arvo Ylppö Medal Award from Finland, the Grand Hamdan International Award on Neonatal Medicine from the United Arab Emirates, and the 2015 Avery Award, a joint award of the SPR/APS honoring Mary Ellen Avery.
Ola Saugstad, University of Oslo
Ola Didrik Saugstad is Professor of Paediatrics and Director of Department of Paediatric Research University of Oslo, Consultant of Neonatology, Oslo University Hospital, Rikshospitalet. He has published Published more than 400 articles—374 articles in peer reviewed journals—and of those, 36 are recorded in Pubmed. His field of interests are newborn oxygenation and resuscitation, oxidative stress and lung injury. Dr. Saugstad has served in supervisory and teaching roles with PHD students and has given over 300 lectures at international congresses and Universities. His numerous awards and honors include the AAP: The Landmark Award 2012, the Nordic Medal Award, 2011 and an honorary professorship from Moscow University in 2013.
Paul Kingma, CCHMC
Paul S. Kingma is the Neonatal Director at the Cincinnati Fetal Center and Associate Professor of Pediatrics Research, UC Department of Pediatrics, and received his PhD in Biochemistry from Vanderbilt University in 2000. He received his residency and fellowship training at Cincinnati Children’s Hospital Medical Center. Dr. Kingma’s research investigates the role of the innate immune system in neonatal infection. Specific projects currently focus on the role of surfactant protein D in neonatal sepsis and acute respiratory distress syndrome and on neutrophil function in cystic fibrosis patients. Paul’s commitment to the future of our scientific community includes the establishment and funding of the Osheroff Science Scholarship that is awarded to top three students in sciences in their junior year at Covenant Christian High School, in his home town of DeMotte, IN.
Maximo Vento, Univ. of Valencia
John is a co-founder and Managing Partner of Triathlon Medical Ventures based in Cincinnati and Executive in Residence at CincyTech. He has 25 years of venture investing and 13 years of research and R&D management experience in biomedical science. John was a Managing Director of Senmed Medical Ventures from 1989 until 2003. Previously, John spent 13 years with Battelle Memorial Institute serving in various research, research management, and business development capacities. John is a member of the Boards of Aerpio Therapeutics, Eccrine Systems, and Chaiman of Airway Therapeutics. He is an observer on the board of CoLucid Pharmaceuticals and and has served previously on the boards of Akebia (AKBA) (Founder and Chairman), Kereos, Syntherix, CS-Keys and as an obvserver at Endocyte (ECYT). John is a member of the board of the Global Cardiovascular Innovation Center at the Cleveland Clinic, Chairman of the Investment Advisory Board of the Harrington Discovery Institute, Innovation Fund Board at Children’s Hospital Medical Center, and the Board of Trustees of Edison Biotechnology Institute of Ohio University. John earned BS, MS and PhD degrees in Microbiology and Virology from The Ohio State University.
Marc Salzberg, MD
Marc has more than 20 years of academic and pharmaceutical experience in the management of drug development and clinical research. He spent several years at Roche’s headquarters in Basel, Switzerland as well as its affiliate in Toronto, Canada. As Head of Clinical Cancer Research at the Basel University, he co-founded and managed a clinical research network in Switzerland (CCRC). Marc was also a founder and President of Pharma Brains, a European boutique CRO, which has been acquired by Medpace, a US based global CRO, after 10 years of successful growth under Marc’s leadership. Marc then served as Vice President of Medical Affairs at Medpace. Marc earned his Medical Doctorate degree from the University of Basel, Switzerland
His medical training and practice includes pediatrics/neotology and oncology.
Jennifer M. Dauer is the Senior Vice President for Strategy & Growth at Cincinnati Children’s Hospital Medical Center. In this capacity, she has responsibility for the Center for Technology Commercialization (CTC) as well as the institution’s strategic planning, business development and Marketing & Communications. Prior to joining the Medical Center, Jennifer was at Procter & Gamble where she served as Vice President/General Manager across several Health & Beauty Care business units. Jennifer received her A.B. from Brown University, where she studied Economics and International Relations. Jennifer also serves as a Member, Director or Observer on numerous Boards for Cincinnati Children’s, including Airway Therapeutics, Assurex, SpineForm and CincyTech.
Mike Venerable is Managing Director at CincyTech, a Cincinnati-based seed stage venture investment company. Since 2007 CincyTech has invested in 54 seed-stage companies in therapeutics, diagnostics, medical devices, software applications, wearables and consumer products. He leads CincyTech’s investment process, working directly with founders to capitalize and build high potential technology companies in Southwest Ohio. He joined CincyTech after returning to Ohio after a 20-year entrepreneurial career in the Washington, DC region, where he cofounded and sold a big data consulting business after working at Oracle and Booz Allen and Hamilton. Earlier he spent four years in the US Army as a Korean linguist and attended the University of Dayton.
AIRWAY represents an interesting investment opportunity for the following reasons:
AT-100 Value Proposition
- AT‐100 (rhSP-D) is a well understood protein
- Anti-microbial and immunomodulator
- Role in surfactant homeostasis
- Massive elevation levels in lung disease
- Patent portfolio supports commercialization
- Manufacturing has been demonstrated
- Pivotal animal study in a clinically relevant model provides significant evidence that AT-100 will improve symptoms and survival in babies born preterm
- Clinical population is well defined
- Orphan designation provides external validation for development path, as well as market and economic incentives